Clinical Data Anticipation: Recent chatter on X about Rezolute, Inc. (RZLT) centers on the upcoming release of pivotal top-line data for their drug Ersodetug in mid-December. Many users are discussing its potential to treat hypoglycemia caused by congenital hyperinsulinism, with high expectations for positive Phase 3 results.
Market Impact Buzz: Posts on X highlight significant market cap speculation, with some predicting a sharp rise if the data impresses. There's also mention of updated price targets from analysts, fueling further debate on the stock’s trajectory. The discussions reflect a mix of optimism and caution as the data release nears.
Note: This discussion summary was generated from an AI condensation of post data.
Rezolute, Inc. Insider Trading Activity
Rezolute, Inc. insiders have traded $RZLT stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RZLT stock by insiders over the last 6 months:
- YOUNG-JIN KIM purchased 1,230,769 shares for an estimated $3,999,999
- DARON EVANS (CFO) has made 2 purchases buying 15,549 shares for an estimated $73,416 and 0 sales.
- BRIAN KENNETH ROBERTS (Chief Medical Officer) purchased 2,500 shares for an estimated $10,939
- NERISSA KREHER purchased 3,076 shares for an estimated $9,997
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Rezolute, Inc. Hedge Fund Activity
We have seen 77 institutional investors add shares of Rezolute, Inc. stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. added 4,870,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $45,778,000
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 2,291,395 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,539,113
- BALYASNY ASSET MANAGEMENT L.P. added 1,822,728 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,133,643
- CALIGAN PARTNERS LP removed 1,543,014 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $14,504,331
- STATE STREET CORP added 1,261,402 shares (+152.0%) to their portfolio in Q3 2025, for an estimated $11,857,178
- BANK OF AMERICA CORP /DE/ added 1,208,408 shares (+1578.5%) to their portfolio in Q3 2025, for an estimated $11,359,035
- WOODLINE PARTNERS LP removed 965,287 shares (-50.7%) from their portfolio in Q3 2025, for an estimated $9,073,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rezolute, Inc. Analyst Ratings
Wall Street analysts have issued reports on $RZLT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/20/2025
- Guggenheim issued a "Buy" rating on 09/22/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for Rezolute, Inc., check out Quiver Quantitative's $RZLT forecast page.
Rezolute, Inc. Price Targets
Multiple analysts have issued price targets for $RZLT recently. We have seen 5 analysts offer price targets for $RZLT in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $17.0 on 11/20/2025
- Jason N. Butler from Citizens set a target price of $17.0 on 10/29/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $15.0 on 09/22/2025
- Jason McCarthy from Maxim Group set a target price of $20.0 on 09/19/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $14.0 on 09/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
